Details of Drug-Drug Interaction
| Drug General Information (ID: DDI4R16D9Y) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Primidone | Drug Info | Hemin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anticonvulsants | Heme Iron Supplement | |||||||
| Structure | |||||||||
| Mechanism of Primidone-Hemin Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Primidone | Hemin | |||||||
| Mechanism | Reduce the pharmacological effect of hemin | Hemin | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ. | ||||||||||||||||||